rapastinel Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Rapastinel (INN) is a novel antidepressant that was under development by Allergan as an adjunctive therapy for the treatment of treatment-resistant depression. It is a centrally active, intravenously administered amidated tetrapeptide that acts as a novel and selective modulator of the NMDA receptor. The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to enhance NMDA receptor-mediated signal transduction and synaptic plasticity.   Wikipedia

Chemistry

  • SMILES: C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N
  • InChIKey: GIBQQARAXHVEGD-BSOLPCOYSA-N
  • Mol. Mass: 413.48
  • ALogP: -2.97
  • ChEMBL Molecule:
    rapastinel  
More Chemistry

Pharmacology

Alternative names

glyx-13 | glyx-13 peptide | rapastinel | tppt-amide

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Automobile Driving (Phase 1)

Depressive Disorder, Major (Phase 3)

Healthy Volunteers (Phase 1)

Memory Disorders (Phase 2)

Obsessive Behavior (Phase 2)

Substance Abuse, Oral (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue